InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Monday, 05/02/2022 11:20:00 AM

Monday, May 02, 2022 11:20:00 AM

Post# of 304
No immunosuppressive regimen needed for in vivo edit

The company also announced the VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the Food and Drug Administration (FDA) due to a determination that there is insufficient information to support dose escalation with the product.

https://www.businesswire.com/news/home/20220502005336/en/Vertex-Provides-Updates-on-Phase-12-Clinical-Trial-of-VX-880-for-the-Treatment-of-Type-1-Diabetes
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DTIL News